Admin_Adham
Jump to Key Points Muscle loss during glucagon-like peptide-1 (GLP-1) receptor agonist therapy was the focus of a lively debate at the American Diabetes Association (ADA) 2026 Scientific Sessions held in June. Here is a brief recap of the debate and its clinical implications.
1. A Lively Debate
One side of the debate argued that GLP-1 induced weight loss is mostly fat mass, with no evidence that it causes frailty or sarcopenia. The opposing side agreed this holds true for typical patients but cautioned that select high-risk groups need closer attention.
2. What the Trial Data Show
Across GLP-1 trials, including Novo Nordisk’s STEP 1 trial of semaglutide, in which participants lost at least 15% of body weight, lean body mass accounted for 25% to 39% of total loss. A subsequent study reanalyzed the reported 39% lean mass loss by accounting for the fluid and protein normally lost from adipose tissue, reducing the figure to 30%. Surgical weight loss studies show a similarly wide range of fat-free mass loss, from 12% to 44%, indicating GLP-1s have no unique effect on body composition.
3. High-Risk Groups
Older adults, menopausal women, and those with sarcopenic obesity warrant close observation since age-related muscle and bone loss accelerates after age 40 and worsens after age 60. Excessive muscle loss in these groups can affect movement, balance, and strength, raising the risk for osteoporosis, frailty, and falls. Additional caution applies to patients with weight cycling, metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea, cardiovascular disease, or body mass index (BMI) under 30.
- GLP-1 wt loss mostly fat; lean mass = 25%–39% of total loss.
- Reanalysis adjusted lean loss to ~30% after fluid/protein correction.
- Surgical wt loss shows similar fat-free mass loss; no unique GLP-1 body-composition effect.
- Older adults, menopausal women, sarcopenic obesity = higher risk for function loss.
- Screen function; resistance exercise + adequate protein help preserve muscle.
4. Comparing Muscle Mass Measurement Tools
Dual-energy X-ray absorptiometry (DEXA) doesn't isolate skeletal muscle mass; it measures fat-free mass, a composite of bone, organs, water, and muscle. Appendicular lean mass is sometimes used as a stand-in, but is an unreliable proxy for true skeletal muscle mass. Deuterated creatine (D3-creatine) dilution directly measures skeletal muscle mass and correlates with physical performance and mortality risk. D3-creatine costs less than magnetic resonance imaging (MRI) or computed tomography (CT) and, unlike CT, avoids ionizing radiation exposure. However, access to D3-creatine remains largely limited to research settings.
5. Practical Safeguards for At-Risk Patients
Before and during GLP-1 therapy in older adults, clinicians should assess physical function and balance using tools such as the Short Physical Performance Battery and Berg Balance Scale. Resistance exercise and adequate dietary protein help preserve muscle mass and function. Investigational drugs such as bimagrumab and enobosarm are being explored as ways to preserve fat-free mass with GLP-1 therapy.
BOTTOM LINE:
GLP-1 induced weight loss is mostly fat, with physical function often improving, and shows no unique effect on body composition compared with other weight loss methods. Still, older adults, menopausal women, and those with sarcopenic obesity warrant closer screening for muscle and function loss. Resistance exercise and adequate dietary protein remain key tools for preserving muscle mass, and emerging agents such as bimagrumab and enobosarm may offer additional options in the future.
This article is based on a recent Medscape article titled " Should We Be Concerned About Muscle Loss With GLP-1s?" and was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
